A Chinese biotechnology start-up, Lonvi Biosciences, claims to have developed a pill that could potentially extend the average human lifespan to 150 years. The Shenzhen-based company says its formula targets 'zombie cells'—ageing cells that refuse to die and cause inflammation and age-related diseases.
The key ingredient, procyanidin C1 (PCC1), is derived from grape seeds. In mouse trials, the company reported a 9.4% increase in overall lifespan, with a 64% extension from the first day of dosing. CEO Ip Zhu described the pill as 'the Holy Grail' of anti-ageing treatments.
Lyu Qinghua, chief technology officer, told The New York Times that living to 150 is 'definitely realistic' and could be achievable 'in a few years.' However, the research remains confined to laboratory settings, with no human trials yet conducted.
China has elevated anti-ageing research to a national priority, alongside AI and biotechnology. The longevity sector has shifted from marginal to mainstream, with significant investment from business leaders. Lonvi claims its PCC1 capsule aims to improve quality of life by reducing age-related deterioration.
